GH240719C25000
- 4.98
- +2.46+97.62%
Guardant Health Newsroom
Guardant Health Analyst Ratings
Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36
Guardant Health Analyst Ratings
Guardant Health Analyst Ratings
Jefferies Initiates Coverage On Guardant Health With Buy Rating, Announces Price Target of $32
Guardant Health Inc: Jefferies starts insurance with a buy rating; target share price is $32
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Vertex Pharmaceuticals (VRTX) and Guardant Health (GH)
Guardant Health Analyst Ratings
Stephens & Co. Reiterates Overweight on Guardant Health, Maintains $44 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Lexaria Bioscience (LEXX) and Guardant Health (GH)
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
Buy Rating Affirmed for Guardant Health Amid Strong Q1 Performance and Positive Revenue Outlook
Analysts Conflicted on These Healthcare Names: Guardant Health (GH), Argenx Se (ARGX) and Annexon Biosciences (ANNX)
Guardant Health Receives 'Buy' Rating on Strong Q1 Performance and Positive Financial Outlook
Piper Sandler Remains a Buy on Guardant Health (GH)
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), Insmed (INSM) and MacroGenics (MGNX)
Craig-Hallum Reaffirms Their Buy Rating on Guardant Health (GH)
Canadian Investment Banking Group: Maintaining the Guardant Health (GH.US) rating, adjusted from buy to buy rating, and adjusted the target price from $45.00 to $30.00.